Structural Characterization of GLP-1 Analogues and Formulations Using Microfluidic Modulation Spectroscopy

Abstract

Glucagon-like peptide-1 (GLP-1) analogues, such as semaglutide and liraglutide, are widely used in treating obesity and type 2 diabetes due to their enhanced stability and prolonged half-life. Their secondary structure plays a critical role in receptor binding stability, and efficacy, making structural characterization vital for drug development and quality control of these peptides. This application note demonstrates how MMS can be used to quantify peptide concentrations and determine structural differences between unmodified GLP-1 and the commercial GLP-1 analogues in different buffer systems, highlighting the advantages of MMS as a biophysical tool for the development of peptide therapeutics.